Genentech Biooncology
Genentech Biooncology
    • Home 

    • Research Education 

    • Research HDIs 

    • What makes HER2 different? 

    • GLOSSARY
    • ON
    • OFF
  • Print
  • share
 
 
' The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
  • Home Page
  • What's New?
  • Tumor Types
  • Molecular Causes of Cancer
  • Biological Pathways
  • Therapeutic Targets
  • Pipeline Molecules
  • Research Education
    • Research ADCs
    • Research Apoptosis
    • Research B cell
    • Research BRAF
    • Research HDIs
      • HER2+ breast cancer
      • HER2 dimerization
      • What makes HER2 different?
      • The structure of HER2
      • The HER2:HER3 dimer
      • Inhibition of HER2 dimerization
      • Slide decks and videos
      • References
      • Glossary
    • Research HER Pathways
    • Research MET
    • Research VEGF
  • Clinical Trials
  • Resources
  • Contact Us
Register for Updates Unsubscribe Share
Register for Updates Unsubscribe Share

Related Resources for this page:

  • Tumor Types
    • Breast Cancer
      • Breast Cancer
  • Molecular Causes of Cancer
    • Apoptosis
      • Resisting cell death
    • Cellular Replication
      • Enabling replicative immortality
    • Growth Signaling
      • Evading growth suppressors
    • Tissue Invasion and Metastasis
      • Activating invasion and metastasis
  • Biological Pathways
    • HER Signaling
      • HER Signaling
    • MAPK Signaling
      • MAPK Signaling
  • Therapeutic Targets
    • HER1
      • HER1
    • HER2
      • HER2
    • HER3
      • HER3
    • HER4
      • HER4
  • Future Directions
    • Antibody-Drug conjugates
      • Summary
      • A brief history of ADCs
      • Cancer effects
      • Current research in ADCs
      • Cytotoxic agent
      • HER2
      • HER ligands
      • HER pathways slide decks and videos
      • Glossary
      • Receptor activation
      • Dimerization
      • HER Signaling
      • Overview
      • HER1/EGFR evaluation
      • HER1/EGFR and prognosis
      • HER1/EGFR as a therapeutic target
      • Summary
      • HER1/EGFR in lung cancer
      • HER1/EGFR in pancreatic cancer
      • HER2 dysregulation
      • HER2:HER3 dimer
      • HER2 and prognosis
      • HER2 detection methods
      • HER2 as a therapeutic target
      • HER2 in breast cancer
      • Summary
      • HER2 in ovarian cancer
      • HER3 dysregulation
      • HER3
      • HER3 evaluation
      • HER3 as a therapeutic target
      • HER3 in breast cancer
      • HER3 in ovarian cancer
      • HER4
      • How are ADCs designed to work?
      • Glossary
      • Monoclonal antibody
      • Multimedia Resources
      • Receptor-Mediated Endocytosis
      • Research ADCs
      • Research MET
      • Stable linker
      • HER receptors
      • Summary
      • Targeting cancers with ADCs
      • Therapeutic potential of HER pathways
      • What are ADCs?
      • What is Met?
    • Glycoengineered Antibodies
      • HER Signaling
    • Non-Antibody Biologics
      • Apoptosis
      • What are the strategies for inhibiting the VEGF pathway?
    • Targeted Small Molecules
      • Summary
      • Cancer effects
      • Apoptosis
      • Resisting apoptosis
      • HER2
      • Gastric Cancer
      • HER ligands
      • HER pathways slide decks and videos
      • Glossary
      • Receptor activation
      • Dimerization
      • Overview
      • HER1/EGFR evaluation
      • HER1/EGFR and prognosis
      • HER1/EGFR as a therapeutic target
      • Summary
      • HER1/EGFR in lung cancer
      • HER1/EGFR in pancreatic cancer
      • HER2 dysregulation
      • HER2:HER3 dimer
      • HER2 and prognosis
      • HER2 detection methods
      • HER2 as a therapeutic target
      • HER2 in breast cancer
      • Summary
      • HER2 in ovarian cancer
      • HER3 dysregulation
      • HER3
      • HER3 evaluation
      • HER3 as a therapeutic target
      • HER3 in breast cancer
      • HER3 in ovarian cancer
      • HER4
      • Glossary
      • MAPK Signaling
      • MEK Inhibitor (GDC-0973)
      • Melanoma
      • PI3K Inhibitor (GDC-0941)
      • Research MET
      • HER receptors
      • Summary
      • PI3K/Akt/mTOR Signaling
      • Therapeutic potential of HER pathways
      • Slide decks and videos
      • What are the strategies for inhibiting the VEGF pathway?
      • What is Met?
    • Traditional Monoclonal Antibodies
      • Summary
      • Anti-EGFL7
      • Cancer effects
      • Glossary
      • HER2
      • Gastric Cancer
      • HER ligands
      • HER pathways slide decks and videos
      • Glossary
      • Receptor activation
      • Dimerization
      • HER Signaling
      • Overview
      • HER1/EGFR evaluation
      • HER1/EGFR and prognosis
      • HER1/EGFR as a therapeutic target
      • Summary
      • HER1/EGFR in lung cancer
      • HER1/EGFR in pancreatic cancer
      • HER2 dysregulation
      • HER2:HER3 dimer
      • HER2 and prognosis
      • HER2 detection methods
      • HER2 as a therapeutic target
      • HER2 in breast cancer
      • Summary
      • HER2 in ovarian cancer
      • HER3 dysregulation
      • HER3
      • HER3 evaluation
      • HER3 as a therapeutic target
      • HER3 in breast cancer
      • HER3 in ovarian cancer
      • HER4
      • Melanoma
      • Research MET
      • HER receptors
      • Summary
      • Angiogenic Signaling
      • Inhibition of HER2 dimerization
      • Therapeutic potential of HER pathways
      • Slide decks and videos
      • What are the strategies for inhibiting the VEGF pathway?
      • What is Met?

Dimerization Video

The Potential Role of Dimerization in HER2+ Breast Cancer Slide Deck

Potential Role of Dimerization


HER2+ Breast Cancer Slide Decks

HER2+ Breast Cancer Slide Decks

Comprehensive overview of HER2 Dimerization Inhibitors (HDIs)


New: HER2 Dimerization iTunes app

New: HER2 Dimerization iTunes app

Explore the potential of HER2 dimerization inhibition

View all downloadable resources
Share

What makes HER2 different?

HER2: a key receptor for dimerization

HER2 is a key receptor for dimerization. HER2 is the only receptor that exists in an "open" conformation, ready to dimerize with other HER family members. Because HER2 is continually ready to dimerize, the overexpression of HER2 promotes the excessive formation of HER2 dimers.3

Preclinical studies also show that HER2-containing dimers have increased signaling potency relative to those without HER2.2

The HER2 receptor

Please note: this video contains sound so please adjust volume

 
  • SITEMAP
  • /
  • PRIVACY POLICY
  • /
  • TERMS & CONDITIONS
  • /
  • CONTACT US
  • /
  • © 2013 Genentech USA, Inc. All rights reserved.
  • /
  • BIO0000574200
Next section: The structure of HER2 »

© 2011 Genentech USA, Inc. All rights reserved